title: [An economic perspective on targeted treatments].
abstract: In the current context of crisis in the field of drug research and patients' increasing demand for greater involvement in the decision-making about their treatment, the possibility of a more personal tailored approach to medicine is emerging. This raises questions about the clinical benefits of targeted therapeutic approaches versus the cost of determining which patients are likely to benefit the most, and protecting the others from the toxicity of inappropriate treatments. Although cost-effectiveness studies shed light on this issue, the conclusions to which they point tend to be obscured by interdependence between the pricing of these tests and the cost of the treatments involved. Investigating the societal willingness-to-pay for gains in QALY (quality adjusted life year) should help to disentangle this interdependence and clarify the conclusions of cost-effectiveness studies.
authors.affiliation: Inserm UMR912, Sciences économiques et sociales de la santé et traitement de l'information médicale (SESSTIM), 13006, Marseille, France - Université Aix Marseille, UMRS912, IRD (Institut de recherche pour le développement), 13006, Marseille, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Seror
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics; D002986:Clinical Trials as Topic; D017046:Cost Savings; D003362:Cost-Benefit Analysis; D005260:Female; D005820:Genetic Testing / Q000191:economics; D006801:Humans; D007348:Insurance, Health; D018579:Patient Selection; D010597:Pharmacogenetics; D057285:Precision Medicine / Q000191:economics*; D019057:Quality-Adjusted Life Years; D035703:Therapies, Investigational / Q000191:economics; D016896:Treatment Outcome